Q2 2026 ALK-Abello A/S Earnings Call Transcript
Key Points
- Strong double-digit revenue growth of 18% in local currencies, driven by tablets and anaphylaxis products.
- Tablet sales exceeded DKK1 billion, up 22%, with strong performance from pediatric indications for ACARIZAX and ITULAZAX.
- Positive progress in China with Phase 3 trial of ACARIZAX expected to complete in Q4, potentially opening a major market.
- Gross margin improved to 68% from 66% due to higher sales volumes, production efficiencies, and favorable sales mix.
- Free cash flow improved significantly to DKK889 million, exceeding expectations, and full-year guidance raised to exceed DKK1 billion.
- German rebate increase from 7% to 15.5% effective January 2027 poses a financial headwind, requiring mitigation efforts.
- Slow uptake of neffy in the UK due to prolonged formulary approvals and administrative processes, impacting launch momentum.
- Capacity costs increased by 22% due to investments in product launches, commercial infrastructure, and R&D, offsetting margin gains.
- Uncertainty in second-half growth due to tough comparisons and timing of shipments to international markets like China and Japan.
- Peanut tablet Phase 3 trial design not yet finalized, with regulatory approvals pending, delaying initiation until end of 2026.
/-- -
Hello, everyone, and welcome to this presentation of ALK's Q2 and first half-year results. Thank you all for joining us.
Let's turn to slide number 2, with an introduction to the speakers and the agenda. My name is Pierre Podnikov, I'm Head of Investor Relations. With me today are CEO, Peter Halling; and CFO, Claus Steensen Sølje.
Peter and Claus will walk you through the quarterly highlights, markets, product trends, and financials. After a brief strategy update, we will return to the full-year outlook, and as usual, we will end the call with a Q&A session.
First, I'll hand you over to Peter to the highlights on slide 3. Please go ahead, Peter.
/- -
Thank you, Per, and thank you all for taking the time to listen to this call. ALK sustained strong sales
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
